Print
Email
Print Edition StoriesTuesday, June 3, 2008
Immune Disease Institute and GlaxoSmithKline in $25M partnership
By Mass High Tech Staff
Immunoinflammation research has brought together pharmaceutical giant GlaxoSmithKline and Boston’s Immune Disease Institute.
The collaboration, a five-year effort worth $25 million, enables the institute and GlaxoSmithKline to draft joint grant proposals through the partnership’s alliance research grant program. The partnership will run through GlaxoSmithKline’s Immuno-Inflammation Centre of Excellence in Drug Discovery.
Under terms of the agreement, GlaxoSmithKline (NYSE:GSK) benefits by getting exclusive rights for IDI immunological developments, and IDI gains competitive strength from the pharmaceutical company in return.
The non-profit Immune Disease Institute, affiliated with Harvard Medical School, provides biomedical research associated with inflammation and immune defense.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
